Clinical: Nitric Oxide Inhalation Therapies

Our laboratory discovered the role of Nitric Oxide (NO) in activating Mtb kinases and shown that at supra physiological concentrations  NO acts as a broad spectrum anti microbial agent. We further identified the mechanism used by mycobacteria to protect against NO induced damage. We translated this research into a clinical drug development program and completed a phase I clinical trial demonstrating the safety of antimicrobial levels of NO given via inhalation. In parallel, we developed NO impregnation technology for medical devices that renders them “self-sterilizing”. We licensed our IP to two  companies, Beyond Air and Enox Biopharma that are  currently conducting clinical trials using NO for treatment of hospital-acquired infections, bronchiolitis and Cystic Fibrosis.